 ablation (EVLA, 4.8%; RFA, 9.7%).
These pooled data had considerable heterogeneity. The
study supported the use of thermal ablation (EVLA or
RFA) for SSV treatment over surgery. A Cochrane review
of three RCTs also found that at a moderate to low level
of evidence, EVLA had resulted in a higher closure rate
at 6 weeks and lower recurrence at 1 year than open